# US 2004/0082579 A1 · Substituted-4-quinolones

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082579 A1
- Document ID: US20040082579A1
- Status: Published application
- Kind: A1
- Application number: 10/450,930
- Filed: 2003-12-01
- Published: 2004-04-29
- Earliest claimed: 2000-12-16
- Assignees: The Secretary of State for Defense
- Inventors: David Idris Pritchard; Barrie Walsham Bycroft; Siri Ram Chhabra; Doreen Hooi
- Web page: https://patentgrep.com/patent/US20040082579A1

## CPC

- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Substituted-4-quinolones of the formula (I): wherein R1 is a straight or branched chain, saturated or ethylenically-unsaturated aliphatic hydrocarbyl group containing 1 to 18 carbon atoms which may optionally be substituted by one or more substituent groups selected from halo, 1-6C alkoxy, carboxy, 1-6C alkoxycarbonyl and NR6R7, wherein each of R6 and R7 is independently selected from H and 1-6C alkyl or R6 and R7 together with the N atom to which they are attached form a saturated heterocyclic group selected from piperidino, piperazino and morpholino. R2 is a group selected from H, —OH, halo, —CHO, —CO2H and CONHR8 wherein R8 is H or a 1-6C alkyl; each of R3, R4 and R1 is independently selected form H, —CH3, —OCH3 and halo; or a non-toxic pharmaceutically-acceptable salt thereof, have use in the manufacture of a medicament for the treatment of a disease of a living animal body, including a human, which disease is responsive to the activity of an immunosuppressant. The preferred compound of the formula 1 is 2-n-heptyl-3-hydroxy-4(1H)-quinolone.

## Claims

### Claim 1

The use of a compound of the formula I
3
wherein R1 is a straight or branched chain, saturated or ethylenically-unsaturated aliphatic hydrocarbyl group containing from 1 to 18 carbon atoms which may optionally be substituted by one or more substituent groups selected from halo, 1-6C alkoxy, carboxy, 1-6C alkoxycarbonyl and NR6R7, wherein each of R1 and R7 is independently selected from H and 1-6C alkyl or R6 and R7 together with the N atom to which they are attached form a saturated heterocyclic group selected from piperidino, piperazino and morpholino; R2 is group selected from H, —OH, halo, —CHO, —CO2H and CONHR8 wherein R8 is H or a 1-6C alkyl; each of R3, R4 and R5 is independently selected from H, —CH3, —OCH3 and halo; or a non-toxic pharmaceutically-acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease of a living animal body, including a human, which disease is responsive to the activity of an immunosuppressant.

### Claim 2 (depends on 1)

The use according to claim 1, wherein the compound has the formula I in which R1 is a straight chain alkyl group having from 3 to 13 carbon atoms.

### Claim 3 (depends on 2)

The use according to claim 2, wherein in the formula I R1 is n-heptyl.

### Claim 4 (depends on 1, 2, 3)

The use according to any one of claims 1 to 3, wherein the formula I R2 is OH.

### Claim 5 (depends on 4)

The use according to claim 4, wherein the compound of the formula I is 2-n-heptyl-3-hydroxy-4(1H-quinolone.

### Claim 6

A method of treating a disease of a living animal body, including a human, which disease is responsive to the activity of an immunosuppressant which method comprises administering to the living animal body, including a human, a therapeutically-effective amount of a compound of the formula I
4
wherein R1 is a straight or branched chain, saturated or ethylenically-unsaturated aliphatic hydrocarbyl group containing from 1 to 18 carbon atoms which may optionally be substituted by one or more substituent groups selected from halo, 1-6C alkoxy, carboxy, 1C alkoxycarbonyl and NR6R7, wherein each of R6 and R7 is independently selected from H and 1-6C alkyl or Rr and R7 together with the N atom to which they are attached form a saturated heterocyclic group selected from piperidino, piperazino and morpholino; R2 is group selected from H, —OH, halo, —CHO, —CO2H and CONHR8 wherein R8 is H or a 1-6C alkyl; each of R3, R4 and R5 is independently selected from H, —CH3, —OCH3 and halo; or a non-toxic pharmaceutically-acceptable salt thereof.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the compound has the formula I in which R1 is a straight chain alkyl group having from 3 to 13 carbon atoms.

### Claim 8 (depends on 7)

The method according to claim 7, wherein in the formula I R1 is n-heptyl.

### Claim 9 (depends on 6, 7, 8)

The method according to any one of claims 6 to 8, wherein the formula I R2 is OH.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the compound of the formula I is 2-n-heptyl-3-hydroxy-4(1H-quinolone.
